Ktel-Block Tablet is a combination antihypertensive medication containing Cilnidipine 10 mg and Telmisartan 40 mg, designed to effectively manage high blood pressure. Cilnidipine, a calcium channel blocker, selectively inhibits L-type and N-type calcium channels, leading to vasodilation of peripheral arteries and reduction of sympathetic nerve activity, thereby decreasing blood pressure. Telmisartan, an angiotensin II receptor blocker (ARB), antagonizes the AT1 receptor, preventing vasoconstriction and aldosterone secretion, which contributes to blood pressure reduction and cardiovascular protection. The synergistic action of these two agents provides enhanced antihypertensive efficacy compared to monotherapy, improving patient compliance by simplifying treatment regimens. Ktel-Block is indicated for the treatment of essential hypertension, helping to reduce the risk of cardiovascular events such as stroke and myocardial infarction. The combination is generally well tolerated, with common adverse effects including dizziness, headache, and mild gastrointestinal disturbances. It is contraindicated in patients with hypersensitivity to either component, severe hepatic impairment, or pregnancy. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Ktel-Block Tablet offers a potent and convenient option for effective blood pressure control in patients requiring combination therapy.